PMID- 19808371
OWN - NLM
STAT- MEDLINE
DCOM- 20091027
LR  - 20220316
IS  - 1941-3297 (Electronic)
IS  - 1941-3289 (Linking)
VI  - 2
IP  - 5
DP  - 2009 Sep
TI  - A pilot trial to assess potential effects of selective intracoronary bone 
      marrow-derived progenitor cell infusion in patients with nonischemic dilated 
      cardiomyopathy: final 1-year results of the transplantation of progenitor cells 
      and functional regeneration enhancement pilot trial in patients with nonischemic 
      dilated cardiomyopathy.
PG  - 417-23
LID - 10.1161/CIRCHEARTFAILURE.109.855023 [doi]
AB  - BACKGROUND: Intracoronary administration of bone marrow-derived progenitor cells 
      (BMC) was shown to improve coronary microvascular function in ischemic heart 
      disease. Because coronary microvascular dysfunction is implicated in the 
      pathogenesis and prognosis of nonischemic dilated cardiomyopathy (DCM), we 
      investigated the effects of intracoronary BMC administration in patients with 
      DCM. METHODS AND RESULTS: Intracoronary infusion of BMC was performed in 33 
      patients with DCM by using an over-the-wire balloon catheter. Left ventricular 
      contractility at baseline and after 3 months was assessed by analysis of left 
      ventricular angiograms. Coronary hemodynamics were determined by intracoronary 
      Doppler wire measurements. After 3 months, regional wall motion of the target 
      area (contractility from -1.08 + or - 0.39 to -0.97 + or - 0.47 SD/chord, 
      P=0.029) and global left ventricular ejection fraction (from 30.2 + or - 10.9 to 
      33.4 + or - 11.5%, P<0.001) were improved. Increase of regional contractile 
      function was directly related to the functionality of the infused cells as 
      measured by their colony-forming capacity. Minimal vascular resistance index was 
      significantly reduced in the BMC-treated vessel after 3 months (from 1.53 + or - 
      0.63 to 1.32 + or -0.61 mm Hg x s/cm; P=0.002, n=24), whereas no changes were 
      observed in the reference vessel (from 1.60 + or - 0.45 to 1.49 + or - 0.45 mm Hg 
      x s/cm; P=0.133, n=13). Twelve months after BMC infusion, N-terminal prohormone 
      brain natriuretic peptide (NT-proBNP) serum levels were decreased, suggesting a 
      beneficial effect on left ventricular remodeling processes (from 1610 + or - 993 
      to 1473 + or - 1147 pg/mL; P=0.038 for logNT-proBNP, n=26). CONCLUSIONS: 
      Intracoronary administration of BMC seems to be associated with improvements in 
      cardiac contractile and microvascular function in patients with DCM. Thus, 
      randomized blinded studies are warranted to evaluate potential clinical benefits 
      of intracoronary BMC administration in patients with DCM.
FAU - Fischer-Rasokat, Ulrich
AU  - Fischer-Rasokat U
AD  - Cardiology and Molecular Cardiology, Department of Medicine III, Goethe 
      University of Frankfurt, Frankfurt/Main, Germany.
FAU - Assmus, Birgit
AU  - Assmus B
FAU - Seeger, Florian H
AU  - Seeger FH
FAU - Honold, Jorg
AU  - Honold J
FAU - Leistner, David
AU  - Leistner D
FAU - Fichtlscherer, Stephan
AU  - Fichtlscherer S
FAU - Schachinger, Volker
AU  - Schachinger V
FAU - Tonn, Torsten
AU  - Tonn T
FAU - Martin, Hans
AU  - Martin H
FAU - Dimmeler, Stefanie
AU  - Dimmeler S
FAU - Zeiher, Andreas M
AU  - Zeiher AM
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090729
PL  - United States
TA  - Circ Heart Fail
JT  - Circulation. Heart failure
JID - 101479941
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - *Bone Marrow Transplantation/methods
MH  - Cardiac Catheterization
MH  - Cardiomyopathy, Dilated/diagnostic imaging/physiopathology/*surgery
MH  - Catheterization
MH  - Cell Proliferation
MH  - *Coronary Circulation
MH  - Echocardiography, Doppler
MH  - Female
MH  - Humans
MH  - Male
MH  - Microcirculation
MH  - Middle Aged
MH  - Myocardial Contraction
MH  - Myocardium/metabolism/*pathology
MH  - Natriuretic Peptide, Brain/blood
MH  - Peptide Fragments/blood
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Recovery of Function
MH  - *Regeneration
MH  - *Stem Cell Transplantation/methods
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Vascular Resistance
MH  - *Ventricular Function, Left
MH  - Ventricular Remodeling
EDAT- 2009/10/08 06:00
MHDA- 2009/10/29 06:00
CRDT- 2009/10/08 06:00
PHST- 2009/10/08 06:00 [entrez]
PHST- 2009/10/08 06:00 [pubmed]
PHST- 2009/10/29 06:00 [medline]
AID - CIRCHEARTFAILURE.109.855023 [pii]
AID - 10.1161/CIRCHEARTFAILURE.109.855023 [doi]
PST - ppublish
SO  - Circ Heart Fail. 2009 Sep;2(5):417-23. doi: 10.1161/CIRCHEARTFAILURE.109.855023. 
      Epub 2009 Jul 29.